97 completed, 10 unknown, 5 active not recruiting, 5 recruiting. 54 Phase 3, 35 Phase 2, 16 Phase 4, 13 Phase 1, 3 Not applicable.
Follow Meningitis, Meningococcal: new trials by email Literature Review of Meningitis, Meningococcal trials Research Report on Meningitis, Meningococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years MPSV-ACYW - Meningococcal Disease; Meningococcal Meningitis | Phase 4 | Not yet recruiting | Zhejiang Provincial Center for Disease Control and Prevention | 200 | 2026-10-20 | 2026-10-21 |
| A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector) Previously vaccinated with MCV4 (CanSino), Previously vaccinated with MPSV4 (LvZhu) - Epidemic Meningitis | Not yet recruiting | CanSino Biologics Inc. | 180 | 2026-09-15 | 2026-08-03 | |
| Metagenomic Analysis of the Pharynx in High Risk Partners Gonorrhea, Neisseria Gonorrhea | Not yet recruiting | Guy's and St Thomas' NHS Foundation Trust | 100 | 2026-07-14 | 2026-06-30 | |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 880 | 2026-03-25 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 1040 | 2026-03-22 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 1040 | 2026-03-22 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years experimental vaccine, active comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Active not recruiting | Sinovac Biotech Co., Ltd | 660 | 2026-03-22 | 2026-08-10 |
| Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine - Meningococcal Meningitis | Phase 1 | Not yet recruiting | Sinovac Life Sciences Co., Ltd. | 150 | 2026-01-21 | 2026-01-28 |
| Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP) - Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis | Phase 1 | Recruiting | CanSino Biologics Inc. | 260 | 2025-12-19 | 2025-12-31 |
| Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons Serogroup B meningococal vaccine - Meningococcal Meningitis, Serogroup B, Transgender Persons | Phase 4 | Recruiting | University Ghent | 250 | 2025-01-31 | 2026-01-20 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 840 | 2024-12-14 | 2026-08-06 |
| Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants MCV4 - Epidemic Meningitis | Phase 4 | Completed | CanSino Biologics Inc. | 3011 | 2024-06-12 | 2026-08-13 |
| A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine - Meningococcal Meningitis | Phase 2 | Unknown | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1200 | 2024-03-20 | 2024-03-29 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1480 | 2024-03-20 | 2026-08-06 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Active not recruiting | CanSino Biologics Inc. | 840 | 2024-03-01 | 2025-07-29 |
| A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age rMenB+OMV NZ - Meningitis, Meningococcal | Phase 4 | Active not recruiting | GlaxoSmithKline | 50 | 2023-11-10 | 2026-04-06 |
| Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) MCV4 - Epidemic Meningitis | Phase 4 | Active not recruiting | CanSino Biologics Inc. | 660 | 2023-09-20 | 2026-03-04 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population MCV4, MSPV4 - Epidemic Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1000 | 2023-09-16 | 2025-07-03 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 3 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1200 | 2021-12-18 | 2024-04-04 |
| Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents MenABCWY vaccine, Placebo - Meningitis, Meningococcal | Phase 2 | Active not recruiting | GlaxoSmithKline | 305 | 2021-11-18 | 2026-09-28 |
Showing 20 of 125. Sign in to see all of them.
Meningococcal Infections (59) · Meningitis (47) · Diphtheria (5) · Tetanus (5) · Haemophilus Infections (4) · Whooping Cough (4) · Chickenpox (3) · Measles (3) · Mumps (3) · Rubella (3) · Central Nervous System Infections (2) · Acquired Immunodeficiency Syndrome (1) · COVID-19 (1) · Coitus (1)
Bacterial Infections (125) · Bacterial Infections and Mycoses (125) · Central Nervous System Bacterial Infections (125) · Central Nervous System Diseases (125) · Gram-Negative Bacterial Infections (125) · Infections (125) · Meningitis, Bacterial (125) · Neisseriaceae Infections (125) · Nervous System Diseases (125) · Neuroinflammatory Diseases (125) · Central Nervous System Infections (123) · Meningitis (78) · Meningococcal Infections (66) · Virus Diseases (10) · RNA Virus Infections (9)
Meningococcal Vaccines (30) · 4CMenB vaccine (10) · MenACWY-CRM vaccine (7) · Heptavalent Pneumococcal Conjugate Vaccine (4) · measles, mumps, rubella, varicella vaccine (4) · Chickenpox Vaccine (3) · Hepatitis A Vaccines (3) · Hepatitis B Vaccines (3) · Measles-Mumps-Rubella Vaccine (3) · MenACWY (3) · Vaccines (3) · 13-valent pneumococcal vaccine (2) · Blood Specimen Collection (2) · CRM197 (non-toxic variant of diphtheria toxin) (2) · Ciprofloxacin (2)
Novartis Vaccines (27) · Sanofi Pasteur, a Sanofi Company (22) · GlaxoSmithKline (9) · CanSino Biologics Inc. (8) · Pfizer (7) · Novartis (5) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (4) · Sinovac Biotech Co., Ltd (4) · Epicentre (3) · JN-International Medical Corporation (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Sanofi (2) · Serum Institute of India Pvt. Ltd. (2) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (2) · Walvax Biotechnology Co., Ltd. (2)
United States (36) · China (19) · Germany (11) · Spain (10) · United Kingdom (9) · Czechia (8) · Finland (8) · Italy (8) · Australia (7) · Puerto Rico (7) · Chile (6) · Poland (6) · Argentina (4) · Brazil (4) · Canada (4)
Alberto Yataco, MD (2) · Lin Du (2) · Abraham Aseffa Aseffa, M.D, PhD (1) · Ahmed Bedru Omer, M.D,Pediatrician (1) · Andrew J. Pollard, MBBS, FRCPCH, PhD (1)
PMID 35164991, PMID 29253560, PMID 17548138, PMID 19048025, PMID 19476428, PMID 19812260, PMID 20164251, PMID 20189491, PMID 20655261, PMID 21148522, PMID 21177912, PMID 21339701, PMID 21389149, PMID 22094635, PMID 22569484, PMID 22832260, PMID 23114372, PMID 23324563, PMID 23352429, PMID 24873986, PMID 25077420, PMID 25308927, PMID 25424810, PMID 25483566, PMID 25969894, PMID 26075813, PMID 26135245, PMID 26232542, PMID 26479973, PMID 26756390, PMID 27745812, PMID 28318767, PMID 28580917, PMID 28646924, PMID 28719502, PMID 29038320, PMID 29789243, PMID 29944651, PMID 30060751, PMID 31110098, PMID 31175126, PMID 31279564, PMID 31327652, PMID 31377946, PMID 32209015, PMID 32209248, PMID 32233959, PMID 32233961, PMID 32387012, PMID 32586928
2017 (5), 2009 (3), 2008 (2), 2014 (2), 2016 (2), 2018 (2), 2005 (1), 2019 (1)